Risk of transfusion‐transmitted infection with severe acute respiratory syndrome coronavirus 2 from blood donors in Japan

Abstract

AbstractBackgroundThe severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) essentially affects respiratory organs and tissues. SARS‐CoV‐2 RNAemia is often associated with more severe cases of coronavirus disease 2019 (COVID‐19) compared to cases without RNAemia. To determine the impact of the pandemic on transfusion medicine, particularly transfusion‐related infection, we examined the frequency of blood donation with RNAemia, the viral RNA (vRNA) concentration, and any possibility of transfusion‐transmitted infection (TTI) among transfusion recipients.Study Design and MethodsvRNA was examined in plasma/serum samples from 496 of 513 blood donors who reported having been infected with SARS‐CoV‐2 within 2 weeks of donation among a total of ca. 9.9 million blood donations in Japan between January 15, 2020, and December 31, 2021. The clinical course of patients transfused with the blood component containing vRNA was also examined.ResultsvRNA was detected in 23 of 496 samples. The median period from blood donation to COVID‐19 onset was 1 day in 16 RNAemia‐positive donors. Most samples had vRNA concentrations below the limit of quantification. Three patients were transfused with either a packed red blood cell or platelet concentrate that tested positive for vRNA, showing no COVID‐19 symptoms and testing negative for vRNA in post‐transfusion blood.ConclusionThe rate of RNAemia was 4.6% among blood donors who were found to be infected with SARS‐CoV‐2 shortly after donation, and vRNA concentrations in their donated blood were extremely low. There was no evidence of TTI in the recipients transfused with RNAemia‐positive blood components. TTI risk in SARS‐CoV‐2 is negligible.